The EU has sanctioned VANFLYTA®, the initial FLT3 inhibitor tailored for recently identified patients with FLT3-ITD positive AML.

Orum Therapeutics has announced a final agreement with Bristol Myers Squibb for the acquisition of its ORM-6151 program.

BioRay introduces the initiation of its Phase I clinical trial with the first patient for BRY812, a new LIV-1 focused antibody drug conjugate.

Ventyx Biosciences reports outcomes of the second phase study of VTX958 in moderate-to-severe plaque psoriasis patients and delivers a company update.

Monte Rosa Therapeutics unveils preclinical findings. The research indicates that MRT-6160, a VAV1-specific molecular glue breaker, may be effective in treating immune-based and inflammatory disorders.

At SITC 2023, ENB Therapeutics showcased preliminary findings from the first phase of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer.

Qualigen Therapeutics reports the initial dosage in the Phase 1a QN-302 Clinical Study for Advanced or Metastatic Solid Tumors has been administered to the first patient.

The FDA greenlights Lilly's Zepbound™ (tirzepatide) - a potent, new choice for managing persistent weight issues, including obesity or overweight cases with health issues connected to weight.

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's.

FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.

MoonLake Immunotherapeutics, a clinical-stage biotech firm, announced encouraging preliminary results from its global Phase 2 ARGO trial. This trial evaluated the efficacy and safety of Nanobody® sonelokimab in patients with active psoriatic arthritis.

Pfizer informed Sosei Group Corporation about initiating a Phase 1 clinical trial with a new oral GLP-1 receptor agonist, PF-06954522, discovered in a joint research venture. Sosei Heptares' StaR® technology was used in the process.